A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 11, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of an independent study showing that the Envisia Genomic Classifier enables physicians to more confidently diagnose idiopathic pulmonary fibrosis (IPF), a progressive lung
View HTML
Toggle Summary Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 9, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced its submission of a De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter ® Dx LymphMark ™ Assay, a novel, genomic lymphoma subtyping test.
View HTML
Toggle Summary Veracyte to Present at the William Blair 40th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 27, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present virtually at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10 , at 12:40
View HTML
Toggle Summary Veracyte to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 21, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 3:30 p.m. Eastern Time .
View HTML
Toggle Summary CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2020-- CareDx, Inc . (Nasdaq: CDNA) and Veracyte, Inc . (Nasdaq: VCYT) today announced an agreement through which CareDx will become the exclusive worldwide commercialization partner for solid organ transplant-rejection tests on the nCounter®
View HTML
Toggle Summary Veracyte to Present at the UBS Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 3:00 p.m. Eastern Time .
View HTML
Toggle Summary Veracyte Announces First Quarter 2020 Financial Results
Total Testing and Product Revenue Increased 20% to $30.4 Million Genomic Testing Volume Grew 15% to 10,559 Executed Exclusive Licensing Agreement with Yale University To Advance Novel, Blood-Based Genomic IPF Monitoring Test on nCounter Platform Company Outlines COVID-19 Impact and Response
View HTML
Toggle Summary Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced that the company has launched “More About You,” a web-based campaign that is designed to educate patients about thyroid nodules, and empower them to both engage in conversations with their
View HTML
Toggle Summary Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Veracyte, Inc. (Nasdaq: VCYT) and Yale University today announced an exclusive licensing agreement to advance the first genomic test for
View HTML
Toggle Summary CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 23, 2020-- Second paragraph, first sentence of release should include Dr. Jose Herazo-Maya , currently Director of Interstitial Lung Disease Program
View HTML